144 related articles for article (PubMed ID: 8867870)
41. Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys.
Minervini V; Disney A; Husbands SM; France CP
Psychopharmacology (Berl); 2020 Oct; 237(10):3057-3065. PubMed ID: 32772146
[TBL] [Abstract][Full Text] [Related]
42. Effect of opioid receptor antagonists on hypothalamic-pituitary-adrenal activity in rhesus monkeys.
Williams KL; Ko MC; Rice KC; Woods JH
Psychoneuroendocrinology; 2003 May; 28(4):513-28. PubMed ID: 12689609
[TBL] [Abstract][Full Text] [Related]
43. Delta opioid-like discriminative stimulus effects of mu opioids in pigeons discriminating the delta opioid BW373U86 from saline.
Picker MJ; Cook CD
Behav Pharmacol; 1998 Jul; 9(4):319-28. PubMed ID: 10065920
[TBL] [Abstract][Full Text] [Related]
44. Receptor reserve and affinity of mu opioid agonists in mouse antinociception: correlation with receptor binding.
Zernig G; Issaevitch T; Broadbear JH; Burke TF; Lewis JW; Brine GA; Woods JH
Life Sci; 1995; 57(23):2113-25. PubMed ID: 7475964
[TBL] [Abstract][Full Text] [Related]
45. The role of endogenous opioids in the luteinizing hormone surge in rats: studies with clocinnamox, a long-lasting opioid receptor antagonist.
Lieberman PB; Woods JH; Young EA
Eur J Pharmacol; 1998 Jul; 352(1):73-9. PubMed ID: 9718270
[TBL] [Abstract][Full Text] [Related]
46. Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.
Zamora JC; Smith HR; Jennings EM; Chavera TS; Kotipalli V; Jay A; Husbands SM; Disney A; Berg KA; Clarke WP
Pharmacol Res Perspect; 2021 Dec; 9(6):e00887. PubMed ID: 34713624
[TBL] [Abstract][Full Text] [Related]
47. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
48. Intravenous self-administration of etonitazene alone and combined with cocaine in rhesus monkeys: comparison with heroin and antagonism by naltrexone and naloxonazine.
Achat-Mendes C; Valdez GR; Platt DM; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2009 Jun; 204(3):489-98. PubMed ID: 19225763
[TBL] [Abstract][Full Text] [Related]
49. Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys.
Maguire DR; France CP
J Pharmacol Exp Ther; 2022 Aug; 382(2):181-187. PubMed ID: 35643857
[TBL] [Abstract][Full Text] [Related]
50. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
51. Behavioral effects of the delta-selective opioid agonist SNC80 and related compounds in rhesus monkeys.
Negus SS; Gatch MB; Mello NK; Zhang X; Rice K
J Pharmacol Exp Ther; 1998 Jul; 286(1):362-75. PubMed ID: 9655881
[TBL] [Abstract][Full Text] [Related]
52. Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys.
Maguire DR; Gerak LR; Woods JH; Husbands SM; Disney A; France CP
J Pharmacol Exp Ther; 2019 Jan; 368(1):88-99. PubMed ID: 30401680
[TBL] [Abstract][Full Text] [Related]
53. In vivo apparent affinity and efficacy estimates for mu opiates in a rat tail-withdrawal assay.
Walker EA; Zernig G; Young AM
Psychopharmacology (Berl); 1998 Mar; 136(1):15-23. PubMed ID: 9537678
[TBL] [Abstract][Full Text] [Related]
54. Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats.
Solinas M; Goldberg SR
Psychopharmacology (Berl); 2005 Jun; 179(4):804-12. PubMed ID: 15619107
[TBL] [Abstract][Full Text] [Related]
55. Interaction of morphine and naltrexone on oral ethanol self-administration in rhesus monkeys.
Williams KL; Kane EC; Woods JH
Behav Pharmacol; 2001 Sep; 12(5):325-33. PubMed ID: 11710747
[TBL] [Abstract][Full Text] [Related]
56. Discriminative stimulus effects of two doses of fentanyl in rats: pharmacological selectivity and effect of training dose on agonist and antagonist effects of mu opioids.
Zhang L; Walker EA; Sutherland J; Young AM
Psychopharmacology (Berl); 2000 Feb; 148(2):136-45. PubMed ID: 10663428
[TBL] [Abstract][Full Text] [Related]
57. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity.
Yoburn BC; Shah S; Chan K; Duttaroy A; Davis T
Pharmacol Biochem Behav; 1995; 51(2-3):535-9. PubMed ID: 7667382
[TBL] [Abstract][Full Text] [Related]
58. Effects of systemically administered dynorphin A(1-17) in rhesus monkeys.
Butelman ER; Harris TJ; Perez A; Kreek MJ
J Pharmacol Exp Ther; 1999 Aug; 290(2):678-86. PubMed ID: 10411578
[TBL] [Abstract][Full Text] [Related]
59. Hydromorphone efficacy and treatment protocol impact on tolerance and mu-opioid receptor regulation.
Kumar P; Sunkaraneni S; Sirohi S; Dighe SV; Walker EA; Yoburn BC
Eur J Pharmacol; 2008 Nov; 597(1-3):39-45. PubMed ID: 18789923
[TBL] [Abstract][Full Text] [Related]
60. Effects of the delta opioid against BW373U86 in pigeons trained to discriminate fentanyl, bremazocine and water in a three-choice drug discrimination procedure.
Negus SS; Morgan D; Cook CD; Picker MJ
Psychopharmacology (Berl); 1996 Aug; 126(3):199-205. PubMed ID: 8876019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
